This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss ...
A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as ...
A rare intracranial brain-recording study revealed that tirzepatide, a GLP-1 and GIP receptor agonist, temporarily silences craving-related neural activity in a key reward circuit of the brain.
Elevated autoantibodies against incretin hormones may indicate poorer outcomes in diabetes, highlighting potential for new ...
This article was reviewed by Darragh O’Carroll, MD. Diabetes Medications for Weight Loss: What to Know Key takeaways: Some ...
Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes medications — also known as GLP-1 and GIP injections — are changing the way we ...
Everyday Health on MSN
Retatrutide Is a New GLP-1 Hit. But Is It Legal?
Retatrutide is a powerful experimental weight loss drug that currently lacks FDA approval. Learn how it works, plus the legal and safety risks of buying retatrutide online.
Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain ...
BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," ...
A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results